Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)

Trial Profile

Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Reltecimod (Primary)
  • Indications Bacterial infections; Soft tissue infections
  • Focus Therapeutic Use
  • Acronyms ACCUTE
  • Sponsors Atox Bio
  • Most Recent Events

    • 23 May 2017 According to an Atox Bio media release, this trial will continue as planned without modification based on the successful completion of pre-specified futility analysis. The recommendation was made by the independent Data Monitoring Committee (DMC) after evaluating efficacy and safety data from the first 102 patients enrolled.
    • 21 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Mar 2019.
    • 21 Nov 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top